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Abstract Purpose Firstly, to give a review of
characteristic indocyanine green angiographic
(ICGA) signs in Vogt–Koyanagi–Harada (VKH)
disease and, secondly, to determine the utility of
ICG angiography in the assessment and follow-up of
choroidal inflammatory activity during initial high-
dose inflammation suppressive therapy and during the
tapering of therapy.
Methods We have first reviewed characteristic
ICGA signs in VKH. This is followed by a study of
four patients with an acute initial VKH uveitis
episode who received regular initial and follow-up
angiographic examinations for at least 9 months.
Classical ICGA signs were recorded at onset and
followed for at least 9 months and were correlated
with treatment levels. The treatment consisted of
high-dose oral corticosteroids (0.8–1.5 mg/kg) pre-
ceded by pulse intravenous methylprednisolone
(500–1000 mg) for 3 days in hyperacute cases and
followed by very slow tapering with the addition of
an immunosuppressive agent in cases of insufficient
response.
Results The major ICGA signs that were both
consistently present and easy to record in the four
VKH patients having an acute initial uveitis episode
with a pre-treatment angiography and an angio-
graphic follow-up for a minimum of 9 months include
(1) early choroidal stromal vessel hyperfluorescence
and leakage, (2) hypofluorescent dark dots, (3) fuzzy
vascular pattern of large stromal vessels and (4) disc
hyperfluorescence. All patients were treated with
high-dose inflammation suppressive therapy: in two
patients, within 14 and 21 days after initial symp-
toms, respectively, and in the other two patients,
within 6 weeks. Hypofluorescent dark dots, the most
constant and easily recordable sign, was very prom-
inent in all cases at presentation. A 90% to complete
resolution of dark dots was noted in all four patients
after 4 months of therapy. The other three major
angiographic signs, early choroidal stromal vessel
hyperfluorescence and leakage, indistinct fuzzy ves-
sels at the intermediate angiographic phase and disc
hyperfluorescence resolved in all cases within 8 weeks
or less of high-dose inflammation suppressive ther-
apy. In three of the four patients, dark dots reap-
peared after a mean of 7.8 ± 2.8 months after onset of
therapy when the patients were under a mean
corticosteroid dose of 13.2 ± 6.3 mg per day without
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any significant clinical or fluorescein angiographic
signs, indicating subclinical recurrence. An increase
in the inflammation suppressive therapy again
brought about angiographic resolution of choroidal
subclinical disease in all cases.
Conclusion Choroidal inflammation shown by
ICG angiography can be suppressed completely by
initial high-dose inflammation suppressive therapy.
However, recurrent subclinical choroidal inflamma-
tion is detected at the end of the tapering period in a
high proportion of cases. This indicates that, in the
absence of an ICGA follow-up, undetected smolder-
ing subclinical disease may persist, thereby explain-
ing the frequently reported evolution towards sunset
glow fundus despite an apparently controlled disease.
This is a clear indication that VKH disease should be
followed by ICG angiography and, in the case of
choroidal subclinical reactivation, a reversal of
therapy tapering and an extension of therapy duration
should be considered.
Keywords Choroiditis  Immunosuppressive
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Vogt–Koyanagi–Harada disease
Introduction
Vogt–Koyanagi–Harada (VKH) disease is thought to
be an autoimmune disease directed against proteins
related to stromal choroidal melanocytes [1, 2]. The
initial inflammatory events therefore occur at the
level of the choroidal stroma, and adjacent structures
such as the retinal pigment epithelium and the retina
are only involved subsequently and secondarily.
Imaging methods that allow the choroidal space to
be visualized are consequently highly indicated for
the initial evaluation and subsequent follow-up and,
occasionally, for the diagnosis of VKH disease. One
of the methods currently used to show the choroidal
space and thereby to diagnoseVKH disease is ultra-
sonography [3]. However, for ultrasonography to be
able to show choroidal involvement, there must be a
certain degree of choroidal thickening, which is only
present in disease which has been progressing for
some time. Ultrasonography is far from sensitive
enough to show early and isolated choroidal foci
(granuloma) or the reappearance of foci in recurrent
disease. Indocyanine green (ICG) angiography has
been shown to be very sensitive, not only in revealing
the presence of small choroidal inflammatory foci but
also in providing information on the choriocapillaris
circulation and on inflammation of the choroidal
stromal vessels [4]. As such, ICG angiography has
proven to be the ideal method to investigate choroidal
disorders as it is sensitive enough to show minimal
and often subclinical changes within the choroid [5–
8]. In cases of suspected VKH disease that do not
have an acute onset, that are seen at a later stage
when sub-optimal therapy has already been intro-
duced or that do not show the complete set of signs,
the diagnosis of VKH becomes more difficult, and
clinicians should not neglect using all available
diagnostic means to reach a diagnosis without delay,
including ICG angiography [9–11].
In this article, we first summarize the characteristic
set of indocyanine green angiographic (ICGA) signs
that can be seen in VKH disease based on earlier
works [12–14]. Using such an established ICG
angiography semiology, the main purpose of the
present work was to follow choroidal involvement in
VKH patients from the early stage of the disease at
the onset of high-dose inflammation suppressive
treatment to the time when treatment had been
tapered to low doses or had been discontinued.
Review of ICGA signs
Standard ICGA protocol for inflammatory
diseases
A standard ICGA protocol for analyzing choroiditis
has been designed and reported earlier [15, 16]. The
angiographic procedure comprises three main phases:
the early phase, up to 2–3 min, which shows
superimposed retinal and choroidal large vessels
and incipient exudation of the dye through the
choriocapillaris into the choroidal stroma; the inter-
mediate phase, at about 10 min, showing maximum
choroidal stromal background fluorescence; the late
phase, from about 22–28 min onwards, depending on
fundus pigmentation, showing wash-out of the dye
from the general circulation, with the large choroidal
vessels appearing dark against the background stro-
mal fluorescence.
174 Int Ophthalmol (2007) 27:173–182
123
Indocyanine green angiographic signs
Indocyanine green angiographic signs in VKH dis-
ease have been identified in the past and are now used
for the initial evaluation and follow-up of VKH
disease in many centers [17–19]. We arbitrarily
subdivided ICGA signs into two classes: main signs,
which are estimated to be the most constant as well as
the most useful and easy to use for evaluation and
follow-up purposes, and minor signs, which are
labeled as such because they have been found to be
less consistent and/or less useful for studying the
evolution of choroidal disease.
Main or major ICGA signs in VKH disease
Early choroidal stromal vessel hyperfluorescence and
leakage indicate severe choroidal stromal inflamma-
tory vasculopathy (Fig. 1). This sign is present in
acute and severe disease and most often slowly
resolves after the initial induction therapy or during
the first 3–6 months of therapy, depending on the
severity of the choroidal inflammatory vasculopathy.
It appears early in angiography and remains present
until removed by diffuse late hyperfluorescence.
Hypofluorescent dark dots, indicating choroidal
foci (granuloma), are the most constant and most
readily recordable angiographic sign that enables
choroidal inflammatory activity to be assessed in a
semi-quantitative manner. By correlating the histo-
pathological information available from choroidal
sections in VKH disease with ICGA dark dots, it can
be hypothesized that the images are generated by the
presence of space-occupying lesions (granuloma).
These granuloma can be of limited size and therefore
not occupying the whole thickness of the choroidal
stroma, or the lesions can be large, occupying the
whole space from sclera to choriocapillaris. These
two types of lesions can be distinguished by ICG
angiography and subclassified into two subtypes:
a. Dark dots present in intermediate phase (8–12
min) and becoming isofluorescent in the late
phase. This pattern indicates the presence of
small, partial thickness inflammatory foci (gran-
uloma) (Fig. 2a, b).
b. Dark dots present up to the late phase (from 20–
22 min onwards). This pattern indicates whole
thickness, large choroidal stromal foci (granu-
loma). The latter type of lesions can also cause
additional choriocapillaris non-perfusion, a sec-
ond cause of hypofluorescence. Obviously, both
patterns do co-exist, indicating inflammatory foci
of different sizes (Fig. 3a, b)
The presence of hypofluorescent dark dots is the
most useful sign for diagnosing subclinical chloroidal
disease and for monitoring the effect of therapy.
However, it has to be stressed that dark dots do not
always mean active granuloma, as they can also
signify stromal scarring. In the latter case, the dark
dots always remain hypofluorescent up to the late
phase. The reason for this is believed to be due to the
lack of diffusion of ICG molecules within these
cicatricial areas as a result of the stroma having
shrunk. This phenomenon is seen when acute disease
has not been treated adequately because the diagnosis
has been delayed, patients have presented late after
the onset of symptoms and/or the dosage of early
therapy has been insufficient. Fundus photography is
usually helpful as it will show dyspigmentation in the
hypofluorescent aeas (Fig. 4a). To determine whether
persisting dark dots are due to active disease or to
Fig. 1 Early choroidal stromal vessel hyperfluorescence and
leakage shown on an early angiographic frame (54 s).
Numerous hyperfluorescent choroidal stromal vessels are
visible, some of which already have a fuzzy appearance from
leakage (upper area of picture). This frame has been kindly
provided by Drs. T.Kawaguchi and M. Mochizuki, Tokyo,
Japan
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scarring, we usually recommend resuming maximal
initial inflammation suppressive therapy, including
intravenous methylprednisolone perfusions, for 3 days
followed first by oral prednisone (1 mg/kg) for 3–
4 weeks and then by a repeat ICG angiography. If
there is no evolution or minor decrease in the
hypofluorescent areas, the persistent dark dots are
probably generated by stromal scars (Fig. 4b).
Fuzzy vascular patterns of large stromal vessels
indicate diffuse inflammatory vasculopathy of the
stromal vessels. This has to be looked for in the
intermediate to late intermediate angiographic phase.
In the late phase, this is succeeded by diffuse stromal
hyperfluorescence (Fig. 5).
Disc hyperfluorescence. The optic disc usually
remains dark and non-fluorescent in a normal ICG
angiography. Disc hyperfluorescence indicates very
severe disease. It usually regresses rapidly following
the initiation of therapy and is therefore a good
indicator to use for evaluating response to initial
high-dose inflammation suppressive therapy (Fig. 6).
Minor ICG angiographic signs
These signs are either not as regularly found as the
major signs or they are of limited use for follow-up
purposes.
Disturbance/delay in early choriocapllaris circu-
lation often seen as irregular choriocapillaris filling
during the early angiographic phase. (Fig. 7).
Hyperfluorescent pinpoints and exudative subreti-
nal hyperfluorescence. In very acute and severe
inflammatory disease, the leaking points at the level
of the retinal pigment epithelium seen on fluorescein
angiography are also apparent on ICG angiography.
In some cases, the subretinal fluid can also be seen on
ICG angiography (Fig. 6).
Fig. 2 (a) Hypofluorescent dark dots erased at the late
angiographic phase (partial thickness choroidal lesions). This
frame was taken at the intermediate phase andshows numerous
hypofluorescent dark dots in the posterior pole and nasal retina.
(b )Hypofluorescent dark dots erased at the late angiographic
phase (partial thickness choroidal lesions). This frame is of the
same area as shown in (a) but is taken at the late angiographic
phase; many of the hypofluorescent dark are no longer visible
because the distribution of indocyanine green (ICG) has been
equalized due to the strong exudation of the ICG molecule
from larger stromal vessels, thus producing a late diffuse
hyperfluorescence
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Diffuse late hyperfluorescence. Diffuse late stro-
mal hyperfluorescence is a regular sign in acute and
subacute disease, but it is difficult to evaluate with
precision as it can be made to be more pronounced
when the gain is pushed up in the angiographic
system. It is therefore difficult to use it as an
evolutional parameter as settings from one angiogra-
phy to another may be different. (Figs. 5, 7).
This enumeration of ICG signs found in VKH is
not exhaustive, and ICG signs are not limited to the
ones presented here. However, the ones mentioned
are probably the more relevant and the most
frequently seen signs.
Patients and methods
Vogt–Koyanagi–Harada patients with an initial acute
inflammatory episode in whom a pre-treatment ICG
angiography had been performed and who had had an
ICG angiographic follow-up of a minimum of
9 months were included in the study. High-dose
inflammation suppressive therapy consisted of either
pulse intravenous methyprednisolone (500–1000 mg)
for 3 days followed by oral corticosteroids at a mean
dose of 50 mg or more for the entire first month and a
tentative tapering plan over 9–12 months in the
absence of recurrence, or oral corticosteroids only, at
the same dosage and with the same tapering schedule.
In the case of insufficient response, cyclosporine was
added to the treatment regimen within the first month.
Standard ophthalmologic examination included the
best corrected visual acuity, slit-lamp examination of
the anterior segment, fundus examination with fundus
photography and laser flare photometry. In cases where
subciliary fluid was suspected,ultrasound biomicros-
copy was performed. The skin was examined for
vitiligo and poliosis, and alopecia were looked for. A
spinal tap to search for monopleiocytosis in the
cerebrospinal fluid was performed in all patients.
Dual fluorescein and ICG angiography following a
standard protocol was performed before the initiation
of therapy and then every month ± 10 days during the
first 4 months and every 2 months ± 1 month there-
after. Indocyanine green angiographic findings were
correlated with clinical findings, fluorescein angio-
graphic signs and with the level of inflammation
suppressive therapy. Particular attention was given to
the kinetics of the four major ICG angiographic signs:
early choroidal stromal vessel hyperfluorescence and
leakage, hypofluorescent dark dots, fuzzy pattern of
large stromal vessels and disc hyperfluorescence.
Fig. 3 (a) Hypofluorescent
dark dots remaining up to
the late angiographic phase
(full thickness choroidal
lesions). This frame was
taken in the intermediate
phase and shows
hypofluorescent dark dots
temporal to the macula.
(b) Hypofluorescent dark
dots remaining up to the late
angiographic phase (full
thickness choroidal lesions).
This frame shows the same
area as (a) taken in the late
angiographic phase and
shows persistence of
hypofluorescent dark dots
temporal to the macula
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Results
Patients, disease characteristics and treatments
From 1995 to 2006 a total of 21 VKH patients were
seen in the uveitis clinic of the Centre for Ophthalmic
Specialized Care (COS), La Source, Lausanne. Four
Fig. 4 (a) Hypofluorescent dark dots indicating choroidal
scarring. Panoramic view of late indocyanine green angio-
graphic (ICGA) phase showing numerous peripheral dark dots
1 week after the initiation of a 3-day intravenous methylpred-
nisolone(1000 mg/day) treatment followed by oral corticoster-
oids (1.5 mg/kg), a treatment regimen started after the patient
had been treated for several weeks with insufficient therapy.
Most of the dark dots did not respond to this pulse therapy,
indicating that the hypofluorescent areas probably correspond
to scarred stromal areas. This was confirmed by the fundus
photography (b) showing numerous dyspigmented areas. (b)
Hypofluorescent dark dots indicating choroidal scarring.
Fundus photography of the same patient as in (a) showing
numerous areas of dyspigmentation; these indicate areas of
past choroidal inflammation that have led to the loss of pigment
and scarring
Fig. 5 Fuzzy vessels in the intermediate phase. This is a case
of acute posterior recurrence 3 years after the initial episode of
Vogt–Koyanagi–Harada disease treated with high-dose inflam-
mation suppressive therapy. Top The choroidal stromal
vascular pattern can no longer be distinguished, and the whole
area is diffusely hyperfluorescent around numerous hypofluo-
rescent dark dots. Bottom The same area is shown only 1 week
after high-dose inflammation suppressive therapy, including
pulse intravenous methylprednisolone (1000 mg/day) for 3 days
followed by oral corticosteroids (1.2 mg/kg). There has been
resolution of most of the hypofluorescent dark dots and there is
a quasi-normal appearance to the choroidal stromal vascular
pattern
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patients qualified for the study having had a pre-
treatment ICG angiography and a regular ICGA
follow-up of a minimum of 9 months. The acute
episode was treated with high-dose inflammation
suppressive therapy within 14–21 days of initial
symptoms in two patients (patients 1 and 2) and
within 6 weeks for the two other patients. The disease
was clinically bilateral for all patients, with the
exception of patient 3, whose involvement of the
right eye could only be detected by ICG angiography
showing all four major signs. Lumbar puncture
showed lymphopleiocytosis in all four patients.
Two patients (patients 1 and 2) had pulse intrave-
nous methyprednisolone (500–1000 mg) for 3 days
followed by oral corticosteroid therapy at a mean dose
of 50 mg or more for the entire first month and a
tentative clinically guided tapering plan over a period
of 9–12 months provided there was no recurrence. Two
patients (patients 3 and 4) had only oral corticosteroids
at the same dosage and the same tapering schedule.
Cyclosporine was added to the treatment regimen
within the first month for two patients.
Clinical findings at presentation
The mean best corrected visual acuity at presentation
was 0.8 ± 0.26. Initial anterior involvement was
present in three of the four patients (five eyes), with a
mean flare measured by laser flare photometry of
113 ± 210.7 ph/ms. Exudative retinal detachments
were present in three of the four patients (five eyes),
and papillitis was present in all patients.
Fluorescein angiographic findings at presentation
Fluorescein angiography showed disc hyperfluores-
cence in all four patients, exudative retinal
Fig. 6 Hyperfluorescent pinpoints, subretinal ICG dye pooling
and disc ICG hyperfluorescence. Hyperacute episode of VKH
showing exudative retinal detachment and hyperfluorescent
pinpoints on fluorescein angiography (left). Due to the severity
of the inflammation, leakage points (hyperfluorescent pin-
points) can also be seen on the ICG angiography as well as
pooling of fluid under the retina, all of which adds to the
diffuse stromal hyperfluorescence. The left picture also shows
ICG disc hyperfluorescence, a consistent ICGA sign in acute
VKH episodes
Fig. 7 Choriocapillaris filling delay. The picture taken 26 s
after dye injection shows a geographic hypofluorescent area
going across the whole fundus from nasal inferior to superior,
indicating a delay in the filling of the choriocapllaris. Nasally
and in the macular area, two hyperfluorescent stromal vessels
can be seen, indicating inflammatory stromal vasculopathy.
This frame has been kindly providedby Drs. T. Kawaguchi and
M. Mochizuki, Tokyo, Japan
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detachments in three patients (five eyes) and irregular
mottled background fluorescence in all four patients
(seven eyes).
Indocyanine green signs at onset and evolution
of ICGA findings
Disc hyperfluorescence was present in all patients and
was the first sign to resolve – within 2 months – after
high-dose inflammation suppressive therapy was
started.
Early choroidal stromal vessel hyperfluorescence
and leakage were present in three patients and
resolved within 3 months after the introduction of
high-dose inflammation suppressive therapy. Indis-
tinct fuzzy choroidal stromal vessels in the interme-
diate angiographic phase was also a constant sign and
had resolved in all patients 3 months after the
initiation of high-dose inflammation suppressive
therapy.
The last angiographic sign to resolve was hypo-
fluorescent dark dots. A 90% resolution of these dots
was obtained in all cases within 4 months following
the initiation of high-dose inflammation suppressive
therapy.
During the tapering of corticosteroid therapy,
choroidal disease recurred in the form of the
reappearance of hypofluorescent dark dots accompa-
nied by the fuzziness of choroidal vessels in three of
the patients after a mean of 7.83 ± 2.84 months. At
this time, the afflicted patients were under a mean
corticosteroid dose of 13.16 ± 6.33 mg/day, with one
patient also receiving 200 mg of cyclosporine.
Neither disc hyperfluorescence nor early hyperfluo-
rescent and leaking choroidal stromal vessels re-
curred during the relapse of choroidal inflammation.
Choroidal rebound inflammation occurred in clini-
cally quiet eyes and in the absence of noticeable
fluoroscein angiographic signs. This rebound choroi-
dal inflammation during therapy taper was success-
fully treated in all patients. In patient 1, oral steroid
doses were re-increased, cyclosporine was main-
tained and mycophenolate mofetyl was added as a
third immunosuppressive drug; at the last follow-up
20 months after disease onset, the patient was
recurrence free but still under therapy. In the second
patient, corticosteroid therapy was increased from
7.5 mg per day to 30 mg. This patient was
subsequently successfully retapered without a recur-
rence of choroidal inflammatory foci (hypofluores-
cent dark dots) and, after a treatment period of
17 months, has been treatment free for 5 months. The
third patient presented a more intense recurrence of
choroidal inflammation and was managed by intra-
venous pulse methylprednisolone therapy followed
by high-dose oral corticosteroid therapy in combina-
tion with cyclosporine. The evolution was character-
ized by several posterior recurrences or panuveitis
that necessitated the continuation of a combination
corticosteroid and cyclosporine therapy for an addi-
tional 8 years. Treatment was complicated by bilat-
eral hip necrosis requiring a bilateral hip replacement.
The patient has now been treatment free for 2 years.
Discussion
The most constant and most relevant ICG angio-
graphic signs for follow-up purposes were hypoflu-
orescent dark dots, which were found in all patients at
presentation. This sign most probably represents
choroidal inflammatory foci. High-dose inflammation
suppressive therapy cleared up these dark dots in all
eyes within approximately 4 months. All other
accompanying signs, including early hyperfluorescent
and leaking choroidal vessels, fuzzy vessels in the
intermediate phase and disc hyperfluorescence, re-
solved even earlier than the hypofluorescent dark
dots. This is understandable as the latter signs are the
expression of a disturbed vascular permeability and,
therefore, they respond much more readily to treat-
ment in comparison to inflammatory foci comprising
accumulated cells infiltrating the stromal space. The
clearance of a granuloma quite clearly takes much
longer than the resolution of abnormal vessel perme-
ability. Surprisingly, the recurrence of hypofluores-
cent dark dots took place in 75% of our patients
(three of the four), even while the patients were still
under low-dose corticosteroid therapy (as well as
additional cyclosporine in one patient) and in the
absence of clinical disease and/or fluorescein angio-
graphic signs. It would appear that in a majority of
cases inflammatory lesions redevelop as soon as the
treatment is no longer at the threshold necessary to
control the autoimmune process. Only the use of ICG
angiography made it possible to demonstrate the
recurrence of choroidal inflammatory lesions as the
latter were silent clinically and were not revealed by
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fluorescein angiography. Thus, only ICG angiography
was able to prove that such subclinical disease was
responsive to increased inflammation suppressive
therapy.
These findings raise several questions. Until
recently it has not been possible to monitor small-
sized choroidal lesions in VKH disease as no method
was sensitive enough to detect lesions that did not
cause disturbance to neighboring structures. There-
fore, any attempt to determine whether the disease
was under control was only based on clinical
examination, which when normal was taken to
indicate no inflammatory activity, and the same was
true for fluorescein angiography. With the availability
of ICG angiography we now have a method sensitive
enough to detect silent inflammatory activity that
seems to be present in a large proportion of patients
for whom disease was thought to be under control.
These findings without a doubt provide the answer for
the unexplained high proportion of VKH cases that
progress towards sunset glow fundus despite the fact
that the disease seemed to be clinically quiet. Indeed,
the very high frequency of sunset glow fundus
reported from all over the world reaches proportions
as high as 89% in Turkey [20], 93% in Japanese
patients with chronic inflammation [21] and 95.8% in
China [22]. Many authors have tried to find an
explanation for the irremediable progression of
disease towards sunset glow fundus even in the
absence of manifest clinical disease, and some have
correlated sunset glow fundus with central nervous
system involvement or inflammatory disease activity
[21, 23]
However, it would be more sensible to correlate
sunset glow fundus with choroidal inflammatory
disease activity and link it directly to this factor.
Based on our data, we suggest that most cases of
VKH disease are under-treated,as subclinical disease
recurred in a high proportion of our cases despite the
fact that very high-dose and prolonged inflammation
suppressive treatment had been given.
We recommend a ICGA-guided follow-up for all
VKH patients in order to better fine-tune the therapy
and to be in a better position to possibly re-increase
therapy as soon as subclinical choroidal recurrence of
the disease is detected. Such a precise follow-up
could be correlated to an objective pixel analysis of
the fundus [24]. This approach may enable clinicians
to avoid the fatal evolution of disease towards sunset
glow fundus, which has been reported in most
studies. On the other hand, such an improved
management may change the behavior of the disease.
At present, most of the recurrences of the disease are
characterized by anterior uveitis as most of the
choroidal pigment has been lost early in disease. The
use of optimized ICG angiography-guided therapy
may increase the probability of posterior recurrences
as the optimal treatment will hopefully have pre-
served most of the choroidal pigment. The number of
patients in this study was small, and our results need
to be substantiated in a prospective study consisting
of a larger number of patients.
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